This program is funded by the state of Indiana’s 21st Century Research & Technology Fund. Eligible Indiana-based companies that have received SBIR/STTR funding are eligible to apply for the program that provides 50% matching funds.
“We’re excited to join the Elevate portfolio and are grateful for their support of Indiana companies,” said Dr. Russell Dahl, Neurodon’s CEO. “These non-dilutive funds from the state of Indiana will allow us to complete critical studies beyond the scope of our original STTR grant and position us favorably for Phase II STTR/SBIR funding from NIH. As an Indiana-based biotech company, we appreciate the resources of the Elevate ecosystem, and we look forward to a relationship with their team.”